Valeant Pharmaceuticals International Inc. picked up the brodalumab torch dropped in May by Amgen Inc., inking an exclusive license with Astrazeneca plc to develop and commercialize the interleukin (IL)-17 inhibitor in moderate to severe plaque psoriasis and psoriatic arthritis (PsA). Read More
Self-administered pain therapy by way of a patient-controlled analgesia (PCA) device in Trevena Inc.'s phase IIb trial let TRV130's attention-getting safety profile emerge, and Wall Street didn't miss the significance, pushing the shares (NASDAQ:TRVN) by the end of the day to $9.05, up $3.05, or 50.8 percent. Read More
Heat Biologics Inc. is winding down a phase II study of its injectable adenocarcinoma cell vaccine, HS-110 (viagenpumatucel-L), in combination with low-dose cyclophosphamide, to focus instead on the potential benefits of combining the vaccine with Opdivo (nivolumab, Bristol-Myers Squibb Co.) to battle non-small-cell lung cancer (NSCLC). Read More
LONDON – Exscientia Ltd. said it has demonstrated its automated medicinal chemistry technology can cut the time and cost taken to design and optimize a drug by 75 percent, while improving the quality of the resulting molecule. Read More
HONG KONG – Although authorities only allow studies linked to stem cells at the moment, the launch of China's first official regulations on stem cell studies may prove to be good news to the country's cell therapy industry. Read More
Amarin Corp. plc and the FDA are trying to settle their differences over what truthful statements the Dublin-based drugmaker may make about off-label uses of its fish oil drug Vascepa. Read More
Allergy Therapeutics plc, of Worthing, UK, said the first patient was enrolled in its Pollinex Quattro birch dose-ranging study conducted in Germany and Austria. Read More
Obseva SA, of Plan-les-Ouates, Switzerland, reported data from ex-vivo pharmacology studies of lead compound, OBE001, at the European Society for Translational Medicine meeting in Vienna. Read More
